BIP Asia 2011

2 December 2011

Dr. Jacqueline C. Lui, Managing Director of Eagle IP Limited, gave a talk on “Why Patent Protection is Required for all Competitive Technologies and Innovations: in China and Worldwide” during the BIP Asia 2011 at the Hong Kong Convention & Exhibition Centre.

Our Past Events

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

21 May 2025

Eagle IP is Coming Back to LSPN in Boston!

24 April 2025

AIPLA Women in IP Global Networking Event in Hong Kong

3 April 2025

Talk at Hong Kong Christian Service

31 October 2024

Talk for HKUST Entrepreneurship 101 Training Program

31 October 2024

IP Training Programme on patent commercialization and technology transfer

8 October 2024

Recommended Insights

China Finally Clamps Down on Facial Recognition Technology

24 August 2021

Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

19 October 2021

The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

10 July 2020

Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021

The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]